CClinicalTrials.gg
Sign In
Not yet recruitingNCT07424456Updated Feb 20, 2026

Comparison Between Triphasic CT Abdomen and EUS-FNB in Characterization of Pancreatic Lesion

An observational study in EUS Guided Biopsy, CT Scan and Pancreatic Lesions Located at the Body or the Tail, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

evaluate the relationship between triphasic CT and EUS findings and the characterization of pancreatic lesions.

Read the detailed description

Comparison Between Triphasic CT and EUS-FNB in characterization of Pancreatic Lesions

02

Conditions studied

  • EUS Guided Biopsy
  • CT Scan
  • Pancreatic Lesions Located at the Body or the Tail

Keywords

  • Triphasic Ct abdomen vs EUS-FNB
  • EUS-FNB
03

In context

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients (age>18 years) presenting with focal pancreatic lesions detected on initial imaging.

Inclusion criteria

  • *Adult patients (age>18 years) presenting with focal pancreatic lesions detected on initial imaging.

    • Patients referred for further evaluation by triphasic CT and/or EUS-guided biopsy.
    • Patients able to provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Previous pancreatic surgery.

    • Known metastatic disease at presentation.
    • Contraindications to contrast-enhanced CT (e.g. severe renal impairment, contrast allergy)
    • Contraindications to EUS or biopsy (e.g., coagulopathy uncorrected, severe cardiopulmonary instability).
    • Pregnancy.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients assessed by Triphasic CT scan

    Triphasic CT scan: Performed using a multidetector CT scanner and CT parameters assessed: Size, shape, and margins of the lesion Enhancement pattern (hypo / iso / hyper-enhancing) Calcifications or cystic components

    Diagnostic Test: Full clinical history (pain, jaundice, weight loss, pancreatitis history). Physical examination with focus on abdominal and systemic findings.

  • Patients assessed by Endoscopic Ultrasound (EUS)&Tissue Sampling

    Performed using linear echoendoscope under conscious sedation or general anesthesia EUS-guided sampling Fine-needle aspiration (FNA) or fine-needle biopsy (FNB) using 19G/22G needles. Multiple passes obtained for cytology and histopathology.

    Diagnostic Test: Full clinical history (pain, jaundice, weight loss, pancreatitis history). Physical examination with focus on abdominal and systemic findings.

Interventions

  • Diagnostic testFull clinical history (pain, jaundice, weight loss, pancreatitis history). Physical examination with focus on abdominal and systemic findings.

    Full clinical history (pain, jaundice, weight loss, pancreatitis history). Physical examination with focus on abdominal and systemic findings.

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of triphasic CT compared to EUS-guided biopsy in differentiating benign from malignant pancreatic lesions.

    the diagnostic accuracy of triphasic CT compared to EUS-guided biopsy in differentiating benign and malignant pancreatic lesions, calculated in terms of sensitivity, specificity, PPV, NPV, and overall accuracy, using final histopathological diagnosis as the reference standard.

    Time frame: one year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Iglesias Garcia J, Larino Noia J, Dominguez Munoz JE. Endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. Rev Esp Enferm Dig. 2009 Sep;101(9):631-8. doi: 10.4321/s1130-01082009000900006. PubMed 19803666 ↗
  • Öztürk B, Ekmen N, et al. The diagnostic role of endoscopic ultrasonography, CT, and MRI in pancreatic cystic lesions. J Clin Med Kaz. 2021;18(4):71-80.
  • Chen J, Sahai AV, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in pancreatic tumors. BMC Gastroenterol. 2012;12:125.
  • Chatterjee A, Shah J. Role of Endoscopic Ultrasound in Diagnosis of Pancreatic Ductal Adenocarcinoma. Diagnostics (Basel). 2023 Dec 28;14(1):78. doi: 10.3390/diagnostics14010078. PubMed 38201387 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07424456
Lead sponsor
Assiut University
Responsible party
Shaza Mamdouh sayed Abd el-galil (Doctor, Assiut University) — Principal investigator
First posted
Feb 20, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Feb 20, 2026

Study contacts

Ahmed Abdullah Ashmawy, Prof. Dr
Contact
rasharma@aun.edu.eg
01005679880
Mohamed Mahdy, ProfDr
Contact
drmohhakim@aun.edu.eg

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Assiut University

Start the discussion